(BOLT) Bolt Biotherapeutics - Ratings and Ratios

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies. The companys lead candidate, BDC-1001, is an IL-2 cytokine-based therapeutic designed to selectively expand tumor-specific T cells while minimizing systemic toxicity. Currently in clinical trials, BDC-1001 targets HER2-positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancers. Bolt is also advancing BDC-3042, a Dectin-2 agonist antibody with a unique mechanism of action targeting innate immunity for a range of cancers, including head and neck, non-small cell lung, ovarian, and triple-negative breast cancer.

Bolt has established strategic collaborations with major biopharmaceutical companies, including Genmab A/S, Innovent Biologics, Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd, as well as a license agreement with Stanford University. These partnerships underscore the companys commitment to leveraging cutting-edge research and accelerating the development of its pipeline. Formerly known as Bolt Therapeutics, Inc., the company rebranded as Bolt Biotherapeutics, Inc. in July 2015 to reflect its expanded focus on biotherapeutic innovation. Headquartered in Redwood City, California, Bolt was incorporated in 2015 and is listed on the NASDAQ under the ticker symbol BOLT.

From a technical perspective, BOLTs stock has shown a declining trend, with its 20-day moving average (SMA20) at $0.47 and 50-day moving average (SMA50) at $0.50, both above the current price of $0.44. The 200-day moving average (SMA200) of $0.63 indicates a broader downtrend. Average trading volume over the past 20 days is 84,577 shares, with an average true range (ATR) of $0.03, reflecting low volatility.

On the fundamental side, Bolt Biotherapeutics has a market capitalization of $19.52 million, with a price-to-book (P/B) ratio of 0.27, suggesting undervaluation relative to book value. The companys price-to-sales (P/S) ratio is 2.00, while return on equity (RoE) stands at -90.36%, highlighting significant losses. With a forward P/E ratio of 0.00, the stock is currently priced without expectation of near-term profitability.